Wilmington, NC, United States
Wilmington, NC, United States

Time filter

Source Type

The report Global Healthcare Analytical Testing Services Market Research Report- Industry Analysis, Size, Share, Growth, Trends And Forecast by DecisionDatabases.com . It provides the value chain analysis, market attractiveness analysis, and company share analysis along with key player’s complete profiles. The global healthcare analytical testing services market research report provides detailed information about the industry based on the revenue (USD MN) for the forecast period. This research study is a descriptive analysis of the healthcare analytical testing services market emphasizing the market drivers and restraints that govern the overall market growth. The trends and future prospects for the market are also included in the report which gives an intellectual understanding of the healthcare analytical testing services industry. Furthermore, the report quantifies the market share held by the major players of the industry and provides an in-depth view of the competitive landscape. The healthcare analytical testing services market is classified into different segments with detailed analysis of each with respect to geography for the study period. A glimpse of the major drivers and restraints affecting this market is mentioned below:   A. Drivers > Nutraceutical industry rising demand > Growing recognition of the QBD (quality by design) approach in pharma research/manufacturing   B. Restraints > Pricing competition faced by major player > Inadequate of expertise The report offers a value chain analysis that gives a comprehensive outlook of the healthcare analytical testing services market. The attractiveness analysis of healthcare analytical testing services market has also been included so as to evaluate the segments that are anticipated to be profitable during the forecast period. The report also studies the competitive landscape of the global market with company profiles of players such as Eurofins Scientific SE, SGS S.A., Charles River Laboratories International Inc., WUXI Pharmatech (Cayman) Inc., PPD Inc., Exova Group PLC, Pace Analytical Services Inc., Intertek Group PLC., Bioreliance Corporation, Source Bioscience, Envigo, Anabiotec, Medistri SA. A detailed description of each has been included, with information in terms of headquarters, inception, stock listing, upcoming capacities, key mergers & acquisitions, financial overview, and recent developments. This analysis gives a thorough idea about the competitive positioning of market players. The report also gives information of healthcare analytical testing services market’s mergers/acquisitions, partnerships, collaborations, new product launches, new product developments and other industry developments. View More about Healthcare Analytical Testing Services Market Research Report @ http://www.decisiondatabases.com/ip/6173-healthcare-analytical-testing-services-market-report   SEGMENTATIONS IN REPORT: 1. Market Analysis by Type: > Bioanalytical Testing Services > Physical Characterization Services > Method Validation > Raw Material Testing > Batch Release Testing Services > Stability Testing > Microbial Testing > Environmental Monitoring   2. Market Analysis by Sample: > Raw Materials > Finished Products > In-Process Samples > Environmental Samples   3. Market Analysis by End User: > Pharmaceutical And Biopharmaceutical Companies > Medical Device Companies > Contract Research Organizations   4. Market Analysis by Geography: > North America > Europe > Asia Pacific > Rest of the World DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.   Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise and meaningful data at a lightning speed.


News Article | March 2, 2017
Site: www.businesswire.com

WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced it has secured the fifth renewal of its long-standing contract with the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The original NIAID/DAIDS contract was awarded in 1990, and with the latest renewal, the relationship will extend until 2024. The renewed contract covers support for a broad scope of research related to HIV or HIV co-infections that includes monitoring therapeutic trials, prevention trials and vaccines work. As part of the relationship, PPD predicts risks to clinical trial participant safety and data integrity based on measures of site performance and other known risk factors. “The extension of this contract will allow PPD to provide important comprehensive clinical site and study monitoring services to the NIH in some of the most pivotal and exciting directions in AIDS research,” said William Sharbaugh, chief operating officer of PPD. “We are privileged to continue our collaborative relationship with the NIH, leveraging our considerable resources as one of the world’s largest CROs, while capitalizing on our in-depth knowledge of infectious diseases.” PPD’s most recent contracts, ranging between five and seven years, have involved monitoring for an average of 150 clinical studies per contract. PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and more than 18,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com. Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s contracts awarded by the NIAID/DAIDS, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: rapid technological advances that make our services or capabilities less competitive; the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; consolidation in the pharmaceutical and biotechnology industries; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.


News Article | February 22, 2017
Site: www.businesswire.com

WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), today announced that it has entered into a collaboration with Frenova Renal Research, a leading drug and medical device contract clinical development services provider dedicated exclusively to renal research. “The opportunity to collaborate with Frenova enhances our ability to connect our clients with researchers recognized as world leaders in the field of nephrology and further strengthens our industry-leading global site and patient capabilities by helping to deliver seamless access to patients, sites and data sources,” said Ulrich Zoeller, vice president, project management, general medicine for PPD. “Frenova’s access to more than two-thirds of all U.S. nephrology patients, coupled with the breadth of its resources and experience in renal research, will enable PPD to continue to build on its already strong presence in nephrology trials.” As part of Fresenius Medical Care North America (FMCNA) - a leading provider of kidney care products and services, and a network of more than 2,200 dialysis centers nationwide - Frenova maintains a world-class network of resources encompassing 260 research sites with 450 principal investigators and access to more than 183,000 active ESRD patients and 390,000 active CKD patients. The breadth and depth of Frenova’s data access is rooted in FMCNA’s unmatched ability to gather and analyze immense amounts of patient data from within the company’s own care ecosystem. The company has collected data on more than 1 million patients, including data on more than 250 million dialysis treatments, more than 1 billion medication administrations and more than 1 billion laboratory results. “Our collaboration with PPD expands the reach of our nephrology experts and broadens the impact of our invaluable treatment data in clinical trials,” said Kurt Mussina, general manager, Frenova. “We are pleased to join forces with PPD through our shared commitment of improving the lives of patients living with kidney disease, around the world, through the advancement of renal research.” Through this relationship, PPD will offer its clients the therapeutic expertise of Frenova’s global nephrology experts, as well as access to F1RST Up™ (Frenova Rapid STart Up), Frenova’s exclusive alliance of research sites designed to streamline, initiate and enroll clinical studies dramatically faster than industry norms with just-in-time patient recruitment. Frenova is active in more than 260 sites across the United States, 15 of which are the proprietary F1RST Up sites with a strong track record of patient recruitment and retention. The F1RST Up sites use coordinated research processes that enable faster site startup and streamlined study execution. PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and more than 18,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com. Frenova is the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research. As a Fresenius Medical Care North America company, Frenova manages a networked system of clinical research assets and resources including 450 principal investigators and 260 research sites with clinical trials in kidney disease and its adjacent medical conditions. For more information, visit www.FrenovaRenalResearch.com. Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about the collaboration with Frenova, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: risks associated with and dependence on strategic relationships; rapid technological advances that make our services or capabilities less competitive; the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; compliance with drug development regulations; changes in the regulation of the drug development process; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.


News Article | December 14, 2016
Site: www.businesswire.com

WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development LLC (PPD) has expanded its stability sample storage capacity and capabilities as part of its ongoing efforts to meet the growing needs of its biopharmaceutical clients. The expansion includes a 75 percent increase in capacity for aliquoting, storage and worldwide distribution of reference standard materials. The new stability operation, which is located at the company’s good manufacturing practices (GMP) lab in Middleton, Wisconsin, was constructed specifically for pharmaceutical storage for its clients and has the capacity to be equipped with more than 120 new stability chambers. The operation will enable the PPD® Laboratories GMP lab to offer a significant expansion of the more than 40 different temperature and humidity set points for routine International Conference on Harmonisation (ICH) stability storage conditions and will increase capacity for customized temperature and humidity, photostability and shipping (freeze/thaw) studies. “The expansion of our stability chamber capabilities in Middleton is indicative of PPD’s ongoing efforts to meet the ever-increasing laboratory needs of our clients around the world,” said Jon Denissen, Ph.D., vice president, GMP Lab, PPD Laboratories. “The GMP lab is representative of PPD Laboratories’ exceptional scientific expertise, broad therapeutic experience and state-of-the-art facilities. During the 22 years we’ve had lab operations in Middleton, we’ve been able to successfully grow our operations due in part to the strength of the talent in the region and the supportive business environment.” With the new stability operation, the company has the capability to expand to 150,000 cubic feet of chamber space, effectively doubling storage capacity for stability programs and for samples of commercially released products that are retained for quality control purposes. It also will allow the Middleton operation to create additional analytical lab space. PPD Laboratories is a leading provider of chemistry, manufacturing and controls (CMC) laboratory services for all phases of drug development. The Middleton GMP lab provides fully integrated solutions for pharmaceutical product development, including analytical testing services, method development and validation, stability testing, quality control and release testing. In addition to small molecule testing, the laboratory is a market leader in the analysis of inhalation and biopharmaceutical/biologic products, as well as extractables and leachables testing. PPD maintains a GMP lab in Athlone, Ireland, to meet the CMC testing needs of the European market. In addition to the GMP labs in Middleton and Athlone, PPD Laboratories has bioanalytical labs in Middleton and Richmond, Virginia; central labs in Shanghai, China; Brussels, Belgium; Highland Heights, Kentucky; and Singapore; a vaccine sciences lab in Richmond; and biomarker labs in Richmond and Highland Heights. For a photo of the stability operation, click here. PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 18,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com. Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about the expansion of PPD’s stability sample storage capacity and capabilities, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; rapid technological advances that make our services or capabilities less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; risks associated with and dependence on strategic relationships; actual operating performance; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.


News Article | February 28, 2017
Site: www.businesswire.com

WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) has established a Rare Disease and Pediatric Center of Excellence to oversee all rare disease and pediatric-related drug development activities. This new center of excellence provides pharmaceutical and biotechnology clients with a dedicated team of professionals focused on the design and execution of clinical trials that address the unique strategic, operational, medical and scientific challenges of clinical studies in rare disease and pediatric patient populations. PPD announced the new center of excellence on Rare Disease Day, which is observed on the last day of February each year to raise awareness of rare diseases. A disease is designated as rare in the United States when it affects fewer than 200,000 people, in Europe when it affects no more than five in 10,000 people and in Japan when it affects fewer than 50,000 people. In the U.S. and Europe alone, as many as 60 million individuals are affected by one of the more than 6,000 identified rare diseases. “Our new center of excellence builds on PPD’s longstanding expertise and experience to address the special drug development considerations of rare diseases and pediatrics,” said Karen Kaucic, M.D., PPD senior vice president and head of the center of excellence. “With a great majority of rare diseases touching children, we believe our approach will enable us to be a more connected and active partner. Our clients can depend on us for the latest trial design innovations, the ability to navigate complex trial logistics and our keen understanding of customized patient access strategies in low-prevalence, widely dispersed patient populations. We felt today was an appropriate time to introduce this new venture, as we join with the drug development community in recognizing Rare Disease Day.” Dr. Kaucic will leverage her leadership experience in rare diseases and pediatrics to drive the implementation of PPD’s center of excellence, leading a dedicated team with a wealth of expertise in rare disease trial design and execution in such disciplines as product development, clinical operations, commercial strategy and early engagement. The PPD team members in the center of excellence are seasoned pharmaceutical and clinical research professionals who have hands-on experience with rare diseases and pediatrics. The team is focused on addressing the specific challenges presented by the small, widely dispersed populations of rare disease and pediatric patients. This group of functional experts has been assembled to support end-to-end clinical trial solutions in such areas as feasibility strategy, clinical information, biostatistics, pharmacovigilance, lab operations and business analytics. PPD’s particular expertise in rare diseases stems from having conducted more than 220 studies with more than 50,000 patients over the past five years. PPD also is a leading clinical researcher in pediatric drug development, having conducted more than 400 clinical trials during the past five years, enrolling more than 97,000 patients across a wide range of therapeutic indications, including infectious diseases, respiratory, cardiology, oncology and immunology. PPD leverages a pediatric investigator network that further enhances its pediatric clinical development capabilities by providing clients with faster trial startup, more predictable patient enrollment and higher-quality data. For both rare disease and pediatric trials, PPD has deployed a purpose-built framework that ensures the application of best practices in study development and enables the company to develop a customized approach to address the unique needs of these trials. PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and more than 18,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com. Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s Rare Disease and Pediatric Center of Excellence contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: risks associated with and dependence on strategic relationships; the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; rapid technological advances that make our services or capabilities less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.


News Article | November 5, 2015
Site: www.businessinsider.com

Photographer William Karl Valentine grew up visiting the Pasadena Police Department, where his father was a reserve police officer. When Valentine enrolled at Arizona State University to study photography, he decided that his first project would be a documentation of the police department. Over the course of four years at ASU, Valentine logged over 1,000 hours shadowing officers in the department, photographing every major operation and event that he was there to witness. What has resulted is a fantastic time capsule of what it was like to be police officer in an LA suburb when the Drug War was in full swing. Valentine shared a number of photos with us here, but you can check out the rest at his website.


News Article | September 28, 2015
Site: www.finsmes.com

The company, which had previously raised $15.9m, intends to use the funds to expand its television advertising and marketing efforts nationwide. Led by Amy Errett, CEO and Co-Founder, Madison Reed delivers a personalized, salon-quality hair color experience to home. Launched in 2013, the company offers a personal process with licensed professional colorists and salon quality hair care products free of ammonia, PPD, resorcinol, and other harsh chemicals.


News Article | August 10, 2015
Site: arstechnica.com

SEATTLE—You know an e-sports event has made it when a crowd's patriotic chants swell into the tens of thousands. But the bigger surprise at this week's The International, currently the largest annual Dota 2 gaming tournament, was that those cries weren't loudest for the usual e-sports titans like Korea or China. This week, capacity crowds celebrated an American squad. On Wednesday night of The International 2015’s main event, I was squeezed into the giant Key Arena crowd watching EHOME—a Chinese legacy team—duke it out with Evil Geniuses—the only North American squad ever to crack the top three at this Dota 2 championship. I was surrounded by streamers, team community managers, members of the press, and a few rowdy friends. A Chinese Dota 2 reporter sat beside me, cheering on each EHOME play with heavily accented English expletives. EHOME slotted snugly into the middle of the packed and stacked Chinese squads (including popular teams like LGD) who had torn through The International's bracket, and the team’s every kill, escape, and feint prompted chants of “EHOME! EHOME!” from the Asian attendees, including my potty-mouthed neighbor. China has dominated the game’s competitive scene year after year, and that streak largely continued at this year's International. Chinese teams occupied two-thirds of the top six placing teams (each of which claimed more than a million dollars from the tournament’s $18 million prize pool). Before the best-of-three series closed, the American fans had matched their opposition's onlookers chant-for-chant throughout the games, but when Evil Geniuses actually won, calls of “USA! USA!” drowned out everything else. At that moment, I exchanged a look with the Asian reporter to my left, who smiled and bashfully put his head in his hands before looking back my way, pumping his fist ever-so-slightly, and softly chanting “USA” just loud enough for the two of us to hear. The scene at the packed-to-the-gills Key Arena was spectacular for six straight days, even Internet outages couldn’t stop the otherwise high-polish proceedings. Every day, Dota 2 fans got to watch roughly 10 matches a day, as e-sports teams from around the world played five-on-five matches and burned through a complicated two-bracket elimination system. Millions of dollars were at stake, including a $6.6 million grand prize. This was no mild, tiptoe-into-Dota-water event, either; attendees were expected to know their Dota 2, and the tourney's slew of commentators spoke rapidly about the game’s various characters and pro-con breakdowns like seasoned sports-radio hosts. The event was a total show of e-sports confidence, making every victory, and every nation-versus-nation face-off, feel that much more like a big deal. I didn’t fully understand it at the time, but Evil Geniuses weren't supposed to go this far. Previously, they had taken North America to the precipice of the grand finals in the largest e-sports tournament in the world (at least in monetary terms) twice. It seemed that once more, America would achieve its little victory—not to mention a $2.2 million prize for third place—and quietly disappear, as usual, in the presence of China and Europe. Instead, winning is for organizations like the aforementioned LGD, or the Legion of Doom-like super-squad Team Secret. Their roster was built from former European champions and talent sniped from Evil Geniuses itself earlier this year, with the obvious goal of winning The International 2015. Many of Western Dota 2 fandom’s anglocentric hopes and dreams rode with Team Secret. And twenty-four hours before the finals, Secret straddled that wave of adulation straight into Seattle’s KeyArena for their first best-of-three series against EHOME. At the head of the current was Arteezy, the highest profile member of Evil Geniuses to be absorbed into Secret’s ranks and a mascot for the latter’s egocentric reputation. He wore the gaudy, golden sunglasses that had been passed out for free somewhere in the stadium and a smirk. What happened next was so perfectly obvious it seemed impossible. Team Secret lost—badly. Their strategies and drafts were straightforward, aggressive, and otherwise predictable—so much so that they may as well have taken a white glove and slapped it across their opponent’s face. The crowd wasn’t scandalized as much as stunned into disbelief. Team Secret exited in defeat with Arteezy’s Nay Bans nowhere to be seen. While surprising, Team Secret's loss to EHOME was nothing compared to the shock when they were eliminated, exiled to share 7th and 8th position by Virtus Pro. Virtus Pro was a middle-of-the-pack contender that, by all indications, should have all but rolled over and died (and they did, one stage later, to LGD Gaming). But short of the grand finale, they may have scored the tournament's most unbelievable result. So arrogance overcame the one Western team that was “supposed” to have a shot at winning. But on paper, there was still Evil Geniuses, despite all the discussion about the Americans being one of the strongest teams in the tournament being hard to swallow. Meanwhile, a little team called CDEC Gaming—the "Chinese Dota Elite Community," which had only just barely qualified for The International—was refusing to lose even a single game to more established teams. To understand Evil Geniuses’ trajectory at this point, you have to understand what every fan of professional Dota 2 from the United States or Canada learns rather quickly: North America is a joke. The region's reputation is so bad that “NA Dota” is a literal punch line—a shorthand meme for the comic relief the region’s teams provide as they form and dissolve in the blink of an eye or produce players with the same cavalier attitude as Arteezy without the skill to back it up. Evil Geniuses are an outlier. The image they project is one of teammates who genuinely like and respect each other. This is the team that makes music videos about how much they love each other using blow-up dolls and Disney songs. This is the team whose captain, after going further than any other North American in history while one of his star players was out with an injury, wrote several hundred words on how it was his fault they didn’t win. For someone who’s followed the departure of Evil Genius Arteezy, and his subsequent replacement with a 16-year-old wunderkind who rode his bike to an Internet cafe in order to play, the team represents a lot more than mere nationalism. Evil Geniuses is a better class of Dota 2 team that rises above the immature and often appalling behavior e-sports can engender (at least most of the time). So it was crushing when they made it to that third-place precipice only to be knocked into the elimination bracket at the last minute by the still undefeated CDEC. This Chinese team had started as underdogs but suddenly looked like a pack of dobermans: sleek, impeccably trained, and with their jaws adamantly clamped around first place. On the final day of The International 2015, LGD Gaming and Evil Geniuses would play for the mere opportunity to face the seemingly unstoppable squad. The loser would walk away with $2.2 million. The winner received at least an extra $600,000 and the dubious proposition of playing up to eight games in a row for the $6.6 million grand prize. Luckily for Evil Geniuses, they eliminated LGD Gaming in just two admittedly arduous rounds. “USA!” resounded again, as well as “EG! EG!” The final match was a total dissection of CDEC’s uncompromising strategies. Fear, Evil Geniuses’ 28-year-old "senior" member (called “Old Man Fear” by the community), backed up Sumail, the 16-year-old prodigy, and his boundless aggression played out like an older brother standing behind a hyperactive sibling. Universe, famous for his level-headedness, dove and disrupted CDEC’s rigid frontline, while Aui_2000 was the string that held them all together—disabling or dealing extra death to the Chinese players where necessary. PPD, the EG team captain, had the faith and understanding of his teammates to draft them exactly the heroes they needed. It was like watching an interpretive dance, telling the story of each player’s personality through steampunk helicopters and $6 million slam dunks. Each of these players has a “real” name to go with their handle, but these are the monikers that those in attendance shouted and tweeted about as the five players hoisted the Aegis of Champions—an ornate metal shield which acts as the championship trophy. At three wins to one, they had become the first North American players to win the finals mere minutes after becoming the first such team to even play in the final match. Confetti matching this year’s gold color scheme doused the stands, while indoor fireworks somehow didn't light the stage's expensive soundproof-booth and super-sized screen rigs on fire. The players’ concussed words of appreciation barely had time to sink in before Deadmau5 appeared as a closing-ceremony musical act and proceeded to do his thing. I wasn’t going to hear another coherent chant from this crowd, amidst the EDM, fire hazards, and guttural excitement at witnessing e-sports history, but that was fine. To see Evil Geniuses win one for the Gipper was exciting, but more importantly the story of Evil Geniuses, which has developed in parts over years, finally culminated in a groundbreaking victory. It was the kind of sports story, full of mentorship, good attitudes, and hard work, that mainstream American sports have severely lacked for some time. I'd call those qualities enough to count e-sports as "legitimate."


WILMINGTON, N.C. & RALEIGH, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) and CISYS LifeSciences today announced PPD’s implementation of Sequence WebEAS, a new Web-based event adjudication system, through a collaboration between the two companies. Sequence WebEAS is a single, comprehensive system that automates and captures all activities, documents and data required for adjudication. It significantly reduces the administrative effort and cost needed by PPD and its biopharmaceutical clients to collect, manage and prepare dossiers for presentation to event adjudication committees (EAC). The system frees committee members to focus on their reviews by providing simple, easy-to-use dashboards and electronic classification forms. “By implementing Sequence WebEAS, PPD will help clients reduce the effort and cost associated with managing adjudication activities,” said Cindy Elko-Simms, M.D., vice president of pharmacovigilance for PPD. “This new system will improve the overall quality of the adjudication process by providing a consistent automated approach to event identification and management. In addition, it will help reduce costs associated with overall project management and data reconciliation by having all adjudication activities and documents captured in one system. At the same time, the convenience and accessibility of Sequence WebEAS make it easy to use for adjudication committee members.” The use of EACs to adjudicate research endpoints is steadily growing, driven by expanding safety requirements, especially those aimed at more rigorous evaluation of cardiovascular risk. The Sequence WebEAS data import function automates the event identification process to automatically pull in event/patient data from various electronic data capture (EDC) systems. Once into the system, the Sequence WebEAS adjudication workflow process automates document collection, dossier preparation, EAC committee selection and scheduling, and dossier distribution. This process enables the system to improve efficiency of activities and quality by maintaining consistency. “Sequence WebEAS enables PPD to establish an efficient, structured and consistent adjudication process, compiling information from various sources to provide reliable and accurate data to adjudication coordinators and committee personnel,” said Jim Saunders, president of CISYS LifeSciences. “The system features role configurable dashboards, intuitive adjudication coordinator and committee member workflow, a robust search engine, powerful edit checks and data validation. The system also has the ability to interface with a variety of EDC platforms and includes many other features that increase compliance and greatly improve process efficiency.” Sequence WebEAS enables EAC members to view all documents and data needed to adjudicate an event/patient through an easy-to-use, Web-based interface that captures all committee actions and retains the reviews of electronic forms. These proprietary interfaces for viewing event/patient data and generating electronic classification forms are highly configurable, allowing committee members to organize and present information to meet the specific needs of the indication. The system’s built-in flexibility accommodates various EAC models and associated workflows. In addition, Sequence WebEAS is 21 CFR Part 11 and HIPAA compliant and validated, and keeps a complete history and audit trail of all activity in the system. Sequence WebEAS provides comprehensive metrics and reporting on all information captured in the system, including dossier preparation activities, the outcome of event/patient assessments, event processing activities and coordinator time usage/efficiency, PPD has provided pharmacovigilance services since 1997 to help biopharmaceutical companies address multiple challenges in fulfilling drug safety obligations. The company’s current holistic offering spans the life cycle from assets in clinical development through market approval and maintenance. Its services include: AE/SAE case management; aggregate report generation; signal detection; global literature surveillance; labeling support; safety review team participation; data safety monitoring board support; adjudication coordination; and safety and periodic report submissions. PPD pharmacovigilance professionals also provide expert functions such as benefit risk management, European qualified person pharmacovigilance and the development of a pharmacovigilance system master file (PSMF). PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 14,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com. CISYS LifeSciences™ is a clinical software engineering firm engaged in the development of technology solutions for the clinical research, pharmaceutical, biotech and health care industries. Since 1990, CISYS has combined high-quality processes, personnel and technology combine to streamline research programs, improve efficiency and make clinical research decisions faster. Sequence, our clinical research platform, is a comprehensive and user-friendly system providing fast and comprehensive clinical research program implementation capabilities for EDC, ePRO, event adjudication, randomization and inventory management, and IWRS/IR. CISYS implements its studies turnkey as an extension of its clients’ clinical team with all levels of support options available. All Sequence platform modules can be run seamlessly integrated or standalone and are 21 CFR Part 11 compliant and fully validated. To learn more about CISYS LifeSciences, go to www.cisys.com. Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about Sequence WebEAS, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; rapid technological advances that make our services or capabilities less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; risks associated with and dependence on strategic relationships; actual operating performance; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.


DURHAM, N.C.--(BUSINESS WIRE)--The 2015 Triangle Walk to Cure Arthritis is seeking to raise $110,000 to help end arthritis. Walk to Cure Arthritis is the Arthritis Foundation’s signature, national fundraising event to prevent, control and cure the nation’s leading cause of disability, and the Triangle Walk will be held on May 2th at the Imperial Center on 4309 Emperor Blvd. in Durham, NC. Arthritis is a crippling disease that impacts more than 50 million adults and 300,000 children – or approximately 22 percent of the United States population. In North Carolina that translates to 1.9 million individuals, including 8,400 children under 19. The disease costs the U.S. economy $128 billion dollars a year, and is a more frequent cause of activity limitation than heart disease, cancer or diabetes. Funds raised through the Triangle Walk to Cure Arthritis will go toward programs, research and advocacy initiatives to help people today while finding a cure for tomorrow. Supporting the efforts of the Arthritis Foundation as Chairs of the 2015 Triangle Walk to Cure Arthritis are Anthony P. Bihl III, CEO of Bioventus, and Dr. Marshall Kuremsky of Triangle Orthopaedic Associates. Under Tony’s leadership as the Corporate Chair in 2014, the Walk to Cure Arthritis achieved unprecedented success in raising more than $98,000, and the Arthritis Foundation is very pleased to have him reprise his role in 2015. “I am again honored to be the Corporate Chair for the Triangle Walk to Cure Arthritis” said Tony. “Although a cure still eludes us, we will keep raising awareness and funds with this Walk and make a difference for thousands of people who are challenged to live with this condition every day.” Bioventus helps bring pain relief to arthritis patients in the U.S. with SUPARTZ® an injectable therapy for the treatment of knee osteoarthritis. For more information visit MyKneeandMe.com. Dr. Marshall Kuremsky of Triangle Orthopaedic Associates has volunteered to serve as Medical Chair of the 2015 Triangle Walk to Cure Arthritis. Dr. Kuremsky is an orthopaedic surgeon who specializes in hand and upper extremity surgery, arthroscopy, and sports medicine, with particular interest in elbow, hand, wrist and shoulder problems Dr. Kuremsky became involved in the Walk as a result of his care for patients with arthritis. “Being involved with the Arthritis Foundation is an honor and a privilege. As part of the leadership for this event for the Foundation I have an opportunity to enhance public awareness and help contribute to the fight against arthritis,” said Dr. Kuremsky. “Many of my patients fear the diagnosis of arthritis because the word itself elicits memories of family or loved ones who have suffered through the pain and dysfunction of arthritis. My hope is for a cure, as well as for improvements in the different types of medical and surgical treatments currently available.” With over 20 locations around the Triangle and central and eastern North Carolina, the staff of Triangle Orthopaedic Associates has continuous exposure to individuals dealing with arthritis, and a strong investment in providing help. For further information on Dr. Kuremsky and Triangle Orthopaedic Associates, please go to www.triangleortho.com. Other local corporate sponsorships include: Long’s Pharmacy, PPD, Littler Mendelson, Subway, Tri Properties and the Sheraton Imperial Hotel To learn more and register for the Triangle Walk to Cure Arthritis, visit WalkToCureArthritisTriangle@kintera.org or contact Candice Fuller at cfuller@arthritis.org, or call 919-250-0433. Striking one in every five adults and 300,000 children, arthritis is the nation’s leading cause of disability. The Arthritis Foundation (www.arthritis.org) is committed to raising awareness and reducing the impact of this serious, painful and unacceptable disease, which can severely damage joints and rob people of living life to its fullest. The Foundation funds life-changing research that has restored mobility in patients for more than six decades; fights for health care policies that improve the lives of the millions who live with arthritis; and partners with families to provide empowering programs and information.

Loading PPD Inc collaborators
Loading PPD Inc collaborators